A non-randomized clinical trial involving 51 r/r B-ALL participants receiving CD19 CAR-T cells showed that extramedullary disease (EMD) other than CNS leukemia was independently associated with the poor survival of B-ALL patients after CAR-T therapy (18). Here, CD19 is linked to central nervous system leukemia.